2010 CMOD Symposium
September 27, 2010 Bethesda, Maryland
Lister Hill Center Auditorium at NIH Campus
Welcome - Intro
Atherothrombosis - Dr. Peter Libby, Brigham and Women’s Hospital
Biomarkers, Inflammation and CRP - Dr. Paul Ridker, Brigham and Women’s Hospital
HDL and CAD – Overview and Update – Dr. Bryan Brewer, Medstar Research Institute
Atherosclerosis Imaging – Dr. Jean-Claude Tardif, Montreal Heart Institute
Imaging Guidelines and Clinical Trial Challenges– Dr. Allen Taylor, Washington Hospital Center
HDL and Imaging in New Product Development – Dr. Eric Coleman, FDA
Biomarker for Diabetes - Dr. Michael Brownlee, Albert Einstein College of Medicine
Diabetes Guidelines and Clinical Trial Challenges – Dr. Hylton Joffe, FDA
Diabetes Guidelines and Clinical Trial Challenges – Dr. Ilan Irony, FDA
Personalized Medicine for the Future of Healthcare - Dr. Clarissa Desjardins, CEPMED
Can Biomarkers Improve Clinical Trial Design – Dr. Douglas Throckmorton, FDA
Health Canada Biomarker Priorities and Initiatives - Dr. Agnes Klein, Health Canada
Predictive Safety Testing Consortium: Renal Biomarker Qualification - Dr. Melanie Blank, FDA
Pharmacoeconomics and Value Assessments of Drugs and Biomarkers - Dr. C. Daniel Mullins, U of Maryland
Use of Biomarkers in Product Development in the Division of Metabolism and Endocrinology - Dr. Mary Parks, FDA
NHLBI Initiatives - Dr. Sonia I. Skarlatos, NHLBI
Case Studies :
Thrombosis
Heart Failure
Non-invasive imaging
Genomics
International Initiatives - Dr. Anders Svensson
International Harmonisation - Dr. Pat O'Mahony
End Panel Discussion